ESC Premium Access

SGLT2 inhibition in diabetes and heart failure: discuss the evidence

Event: ESC CONGRESS 2016
Topic: Diabetes management
Session type: EBAC Accredited Educational Programme - Experts on the Spot
Organised by Academic Medical Center Amsterdam. Dept Vascular Medicine and Physicians' Academy for Cardiovascular Education / Course Director: Prof John Kastelein / Supported by an unrestricted educational grant from Boehringer Ingelheim/Lilly
Date: 29 August 2016
Time: 10:15 - 10:45

Session

3 presentations in this session

Introduction - SGLT2 inhibition in diabetes and heart failure: discuss the evidence.

Speaker: Doctor D. Fitchett (Toronto, CA)
Thumbnail

SGLT2 inhibition: exploring the evidence in diabetes and heart failure.

Speaker: Professor J. McMurray (Glasgow, GB)
Thumbnail

Interactive discussion: what are the implications of SGLT2 inhibition in HF patients with diabetes?

Speaker: Doctor D. Fitchett (Toronto, CA)
Speaker: Professor J. McMurray (Glasgow, GB)
Thumbnail

4 speakers from this session

Doctor David Fitchett

St. Michael's Hospital, Toronto (Canada)
16 presentations
0 follower

Professor John J V McMurray

Western Infirmary, Glasgow (United Kingdom of Great Britain & Northern Ireland)
82 presentations
2 followers

Doctor David Fitchett

St. Michael's Hospital, Toronto (Canada)
16 presentations
0 follower

Professor John J V McMurray

Western Infirmary, Glasgow (United Kingdom of Great Britain & Northern Ireland)
82 presentations
2 followers

This platform is supported by

logo Novo Nordisk